Cross talk between two antioxidant systems, thioredoxin and DJ-1: Consequences for cancer

Oncoscience

Volumn 1, Issue 1, 2014, Pages 95-110

  Raninga, Prahlad V ^a   Di Trapani, Giovanna ^a   Tonissen, Kathryn F ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

Antioxidants; Cancer; DJ 1; Oxidative stress; Redox signalling; Thioredoxin

Indexed keywords

EID: 84927514796     PISSN: None     EISSN: 23314737     Source Type: Journal    
DOI: 10.18632/oncoscience.12     Document Type: Article

References (135)

1. Robbins D and Zhao Y. Oxidative Stress Induced by MnSOD-p53 Interaction: Pro-or Anti-Tumorigenic? J Signal Transduct. 2012; 2012: 101465.
2. Finkel T. Oxidant signals and oxidative stress. Curr Opin Cell Biol. 2003; 15: 247-254.
3. Martindale JL and Holbrook NJ. Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol. 2002; 192: 1-15.
4. Kabe Y, Ando K, Hirao S, Yoshida M and Handa H. Redox regulation of NF-kappaB activation: distinct redox regulation between the cytoplasm and the nucleus. Antioxid Redox Signal. 2005; 7: 395-403.
5. Sun Y and Oberley LW. Redox regulation of transcriptional activators. Free Radic Biol Med. 1996; 21: 335-348.
6. Sasaki H, Galang N and Maulik N. Redox regulation of NFkappaB and AP-1 in ischemic reperfused heart. Antioxid Redox Signal. 1999; 1: 317-324.
7. Na HK, Kim EH, Choi MA, Park JM, Kim DH and Surh YJ. Diallyl trisulfide induces apoptosis in human breast cancer cells through ROS-mediated activation of JNK and AP-1. Biochem Pharmacol. 2012; 84: 1241-1250.
8. Ryter SW, Kim HP, Hoetzel A, Park JW, Nakahira K, Wang X and Choi AM. Mechanisms of cell death in oxidative stress. Antioxid Redox Signal. 2007; 9: 49-89.
9. Holmgren A. Thioredoxin. Annu Rev Biochem. 1985; 54: 237-271.
10. Lu J and Holmgren A. The thioredoxin antioxidant system. Free Radic Biol Med. 2013.
11. Fernandes AP and Holmgren A. Glutaredoxins: glutathionedependent redox enzymes with functions far beyond a simple thioredoxin backup system. Antioxid Redox Signal. 2004; 6: 63-74.
12. Rhee SG, Chae HZ and Kim K. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med. 2005; 38: 1543-1552.
13. Clements CM, McNally RS, Conti BJ, Mak TW and Ting JP. DJ-1, a cancer-and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc Natl Acad Sci U S A. 2006; 103: 15091-15096.
14. Zhou W and Freed CR. DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T alphasynuclein toxicity. J Biol Chem. 2005; 280: 43150-43158.
15. Iwao-Koizumi K, Matoba R, Ueno N, Kim SJ, Ando A, Miyoshi Y, Maeda E, Noguchi S and Kato K. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol. 2005; 23: 422-431.
16. Kim SJ, Miyoshi Y, Taguchi T, Tamaki Y, Nakamura H, Yodoi J, Kato K and Noguchi S. High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer. Clin Cancer Res. 2005; 11: 8425-8430.
17. Lincoln DT, Ali Emadi EM, Tonissen KF and Clarke FM. The thioredoxin-thioredoxin reductase system: overexpression in human cancer. Anticancer Res. 2003; 23: 2425-2433.
18. Fernandes AP, Capitanio A, Selenius M, Brodin O, Rundlof AK and Bjornstedt M. Expression profiles of thioredoxin family proteins in human lung cancer tissue: correlation with proliferation and differentiation. Histopathology. 2009; 55: 313-320.
19. Park JH, Kim YS, Lee HL, Shim JY, Lee KS, Oh YJ, Shin SS, Choi YH, Park KJ, Park RW and Hwang SC. Expression of peroxiredoxin and thioredoxin in human lung cancer and paired normal lung. Respirology. 2006; 11: 269-275.
20. Li C, Thompson MA, Tamayo AT, Zuo Z, Lee J, Vega F, Ford RJ and Pham LV. Over-expression of Thioredoxin-1 mediates growth, survival, and chemoresistance and is a druggable target in diffuse large B-cell lymphoma. Oncotarget. 2012; 3: 314-326.
21. Poerschke RL and Moos PJ. Thioredoxin reductase 1 knockdown enhances selenazolidine cytotoxicity in human lung cancer cells via mitochondrial dysfunction. Biochem Pharmacol. 2011; 81: 211-221.
22. He T, Banach-Latapy A, Vernis L, Dardalhon M, Chanet R and Huang ME. Peroxiredoxin 1 knockdown potentiates beta-lapachone cytotoxicity through modulation of reactive oxygen species and mitogen-activated protein kinase signals. Carcinogenesis. 2013; 34: 760-769.
23. Honeggar M, Beck R and Moos PJ. Thioredoxin reductase 1 ablation sensitizes colon cancer cells to methylseleninatemediated cytotoxicity. Toxicol Appl Pharmacol. 2009; 241: 348-355.
24. Nagakubo D, Taira T, Kitaura H, Ikeda M, Tamai K, Iguchi-Ariga SM and Ariga H. DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem Biophys Res Commun. 1997; 231: 509-513.
25. MacKeigan JP, Clements CM, Lich JD, Pope RM, Hod Y and Ting JP. Proteomic profiling drug-induced apoptosis in non-small cell lung carcinoma: identification of RS/DJ-1 and RhoGDIalpha. Cancer Res. 2003; 63: 6928-6934.
26. Hod Y. Differential control of apoptosis by DJ-1 in prostate benign and cancer cells. J Cell Biochem. 2004; 92: 1221-1233.
27. Kim RH, Peters M, Jang Y, Shi W, Pintilie M, Fletcher GC, DeLuca C, Liepa J, Zhou L, Snow B, Binari RC, Manoukian AS, Bray MR, Liu FF, Tsao MS and Mak TW. DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell. 2005; 7: 263-273.
28. Shu K, Xiao Z, Long S, Yan J, Yu X, Zhu Q and Mei T. Expression of DJ-1 in Endometrial Cancer: Close Correlation With Clinicopathological Features and Apoptosis. Int J Gynecol Cancer. 2013; 23: 1029-1035.
29. Le Naour F, Misek DE, Krause MC, Deneux L, Giordano TJ, Scholl S and Hanash SM. Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin Cancer Res. 2001; 7: 3328-3335.
30. Pardo M, Garcia A, Thomas B, Pineiro A, Akoulitchev A, Dwek RA and Zitzmann N. The characterization of the invasion phenotype of uveal melanoma tumour cells shows the presence of MUC18 and HMG-1 metastasis markers and leads to the identification of DJ-1 as a potential serum biomarker. Int J Cancer. 2006; 119: 1014-1022.
31. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, Dekker MC, Squitieri F, Ibanez P, Joosse M, van Dongen JW, Vanacore N, van Swieten JC, Brice A, Meco G, van Duijn CM, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2003; 299: 256-259.
32. Gorner K, Holtorf E, Odoy S, Nuscher B, Yamamoto A, Regula JT, Beyer K, Haass C and Kahle PJ. Differential effects of Parkinson's disease-associated mutations on stability and folding of DJ-1. J Biol Chem. 2004; 279: 6943-6951.
33. Macedo MG, Anar B, Bronner IF, Cannella M, Squitieri F, Bonifati V, Hoogeveen A, Heutink P and Rizzu P. The DJ-1L166P mutant protein associated with early onset Parkinson's disease is unstable and forms higher-order protein complexes. Hum Mol Genet. 2003; 12: 2807-2816.
34. Miller DW, Ahmad R, Hague S, Baptista MJ, Canet-Aviles R, McLendon C, Carter DM, Zhu PP, Stadler J, Chandran J, Klinefelter GR, Blackstone C and Cookson MR. L166P mutant DJ-1, causative for recessive Parkinson's disease, is degraded through the ubiquitin-proteasome system. J Biol Chem. 2003; 278: 36588-36595.
35. Honbou K, Suzuki NN, Horiuchi M, Niki T, Taira T, Ariga H and Inagaki F. The crystal structure of DJ-1, a protein related to male fertility and Parkinson's disease. J Biol Chem. 2003; 278: 31380-31384.
36. Tao X and Tong L. Crystal structure of human DJ-1, a protein associated with early onset Parkinson's disease. J Biol Chem. 2003; 278: 31372-31379.
37. Lee SJ, Kim SJ, Kim IK, Ko J, Jeong CS, Kim GH, Park C, Kang SO, Suh PG, Lee HS and Cha SS. Crystal structures of human DJ-1 and Escherichia coli Hsp31, which share an evolutionarily conserved domain. J Biol Chem. 2003; 278: 44552-44559.
38. Wilson MA, Collins JL, Hod Y, Ringe D and Petsko GA. The 1.1-A resolution crystal structure of DJ-1, the protein mutated in autosomal recessive early onset Parkinson's disease. Proc Natl Acad Sci U S A. 2003; 100: 9256-9261.
39. Huai Q, Sun Y, Wang H, Chin LS, Li L, Robinson H and Ke H. Crystal structure of DJ-1/RS and implication on familial Parkinson's disease. FEBS Lett. 2003; 549: 171-175.
40. Du X, Choi IG, Kim R, Wang W, Jancarik J, Yokota H and Kim SH. Crystal structure of an intracellular protease from Pyrococcus horikoshii at 2-A resolution. Proc Natl Acad Sci U S A. 2000; 97: 14079-14084.
41. Yanagida T, Tsushima J, Kitamura Y, Yanagisawa D, Takata K, Shibaike T, Yamamoto A, Taniguchi T, Yasui H, Taira T, Morikawa S, Inubushi T, Tooyama I and Ariga H. Oxidative stress induction of DJ-1 protein in reactive astrocytes scavenges free radicals and reduces cell injury. Oxid Med Cell Longev. 2009; 2: 36-42.
42. Koide-Yoshida S, Niki T, Ueda M, Himeno S, Taira T, Iguchi-Ariga SM, Ando Y and Ariga H. DJ-1 degrades transthyretin and an inactive form of DJ-1 is secreted in familial amyloidotic polyneuropathy. Int J Mol Med. 2007; 19: 885-893.
43. Kim SJ, Park YJ, Hwang IY, Youdim MB, Park KS and Oh YJ. Nuclear translocation of DJ-1 during oxidative stressinduced neuronal cell death. Free Radic Biol Med. 2012; 53: 936-950.
44. Maita C, Tsuji S, Yabe I, Hamada S, Ogata A, Maita H, Iguchi-Ariga SM, Sasaki H and Ariga H. Secretion of DJ-1 into the serum of patients with Parkinson's disease. Neurosci Lett. 2008; 431: 86-89.
45. Takahashi K, Taira T, Niki T, Seino C, Iguchi-Ariga SM and Ariga H. DJ-1 positively regulates the androgen receptor by impairing the binding of PIASx alpha to the receptor. J Biol Chem. 2001; 276: 37556-37563.
46. Shinbo Y, Taira T, Niki T, Iguchi-Ariga SM and Ariga H. DJ-1 restores p53 transcription activity inhibited by Topors/p53BP3. Int J Oncol. 2005; 26: 641-648.
47. Zhong N, Kim CY, Rizzu P, Geula C, Porter DR, Pothos EN, Squitieri F, Heutink P and Xu J. DJ-1 transcriptionally up-regulates the human tyrosine hydroxylase by inhibiting the sumoylation of pyrimidine tract-binding proteinassociated splicing factor. J Biol Chem. 2006; 281: 20940-20948.
48. Zhou W, Zhu M, Wilson MA, Petsko GA and Fink AL. The oxidation state of DJ-1 regulates its chaperone activity toward alpha-synuclein. J Mol Biol. 2006; 356: 1036-1048.
49. Chen J, Li L and Chin LS. Parkinson disease protein DJ-1 converts from a zymogen to a protease by carboxyl-terminal cleavage. Hum Mol Genet. 2010; 19: 2395-2408.
50. Canet-Aviles RM, Wilson MA, Miller DW, Ahmad R, McLendon C, Bandyopadhyay S, Baptista MJ, Ringe D, Petsko GA and Cookson MR. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci U S A. 2004; 101: 9103-9108.
51. Junn E, Jang WH, Zhao X, Jeong BS and Mouradian MM. Mitochondrial localization of DJ-1 leads to enhanced neuroprotection. J Neurosci Res. 2009; 87: 123-129.
52. Lev N, Ickowicz D, Barhum Y, Lev S, Melamed E and Offen D. DJ-1 protects against dopamine toxicity. J Neural Transm. 2009; 116: 151-160.
53. Taira T, Saito Y, Niki T, Iguchi-Ariga SM, Takahashi K and Ariga H. DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep. 2004; 5: 213-218.
54. Lev N, Ickowicz D, Melamed E and Offen D. Oxidative insults induce DJ-1 upregulation and redistribution: implications for neuroprotection. Neurotoxicology. 2008; 29: 397-405.
55. Takahashi-Niki K, Niki T, Taira T, Iguchi-Ariga SM and Ariga H. Reduced anti-oxidative stress activities of DJ-1 mutants found in Parkinson's disease patients. Biochem Biophys Res Commun. 2004; 320: 389-397.
56. Yokota T, Sugawara K, Ito K, Takahashi R, Ariga H and Mizusawa H. Down regulation of DJ-1 enhances cell death by oxidative stress, ER stress, and proteasome inhibition. Biochem Biophys Res Commun. 2003; 312: 1342-1348.
57. Kinumi T, Kimata J, Taira T, Ariga H and Niki E. Cysteine-106 of DJ-1 is the most sensitive cysteine residue to hydrogen peroxide-mediated oxidation in vivo in human umbilical vein endothelial cells. Biochem Biophys Res Commun. 2004; 317: 722-728.
58. Im JY, Lee KW, Junn E and Mouradian MM. DJ-1 protects against oxidative damage by regulating the thioredoxin/ASK1 complex. Neurosci Res. 2010; 67: 203-208.
59. Kim YC, Kitaura H, Taira T, Iguchi-Ariga SM and Ariga H. Oxidation of DJ-1-dependent cell transformation through direct binding of DJ-1 to PTEN. Int J Oncol. 2009; 35: 1331-1341.
60. Shendelman S, Jonason A, Martinat C, Leete T and Abeliovich A. DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation. PLoS Biol. 2004; 2: e362.
61. Blackinton J, Lakshminarasimhan M, Thomas KJ, Ahmad R, Greggio E, Raza AS, Cookson MR and Wilson MA. Formation of a stabilized cysteine sulfinic acid is critical for the mitochondrial function of the parkinsonism protein DJ-1. J Biol Chem. 2009; 284: 6476-6485.
62. Waak J, Weber SS, Gorner K, Schall C, Ichijo H, Stehle T and Kahle PJ. Oxidizable residues mediating protein stability and cytoprotective interaction of DJ-1 with apoptosis signal-regulating kinase 1. J Biol Chem. 2009; 284: 14245-14257.
63. Mo JS, Jung J, Yoon JH, Hong JA, Kim MY, Ann EJ, Seo MS, Choi YH and Park HS. DJ-1 modulates the p38 mitogen-activated protein kinase pathway through physical interaction with apoptosis signal-regulating kinase 1. J Cell Biochem. 2010; 110: 229-237.
64. Choi J, Sullards MC, Olzmann JA, Rees HD, Weintraub ST, Bostwick DE, Gearing M, Levey AI, Chin LS and Li L. Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. J Biol Chem. 2006; 281: 10816-10824.
65. Nishinaga H, Takahashi-Niki K, Taira T, Andreadis A, Iguchi-Ariga SM and Ariga H. Expression profiles of genes in DJ-1-knockdown and L 166 P DJ-1 mutant cells. Neurosci Lett. 2005; 390: 54-59.
66. Eberle D, Hegarty B, Bossard P, Ferre P and Foufelle F. SREBP transcription factors: master regulators of lipid homeostasis. Biochimie. 2004; 86: 839-848.
67. Yamaguchi S, Yamane T, Takahashi-Niki K, Kato I, Niki T, Goldberg MS, Shen J, Ishimoto K, Doi T, Iguchi-Ariga SM and Ariga H. Transcriptional activation of low-density lipoprotein receptor gene by DJ-1 and effect of DJ-1 on cholesterol homeostasis. PLoS One. 2012; 7: e38144.
68. Niki T, Takahashi-Niki K, Taira T, Iguchi-Ariga SM and Ariga H. DJBP: a novel DJ-1-binding protein, negatively regulates the androgen receptor by recruiting histone deacetylase complex, and DJ-1 antagonizes this inhibition by abrogation of this complex. Mol Cancer Res. 2003; 1: 247-261.
69. Tillman JE, Yuan J, Gu G, Fazli L, Ghosh R, Flynt AS, Gleave M, Rennie PS and Kasper S. DJ-1 binds androgen receptor directly and mediates its activity in hormonally treated prostate cancer cells. Cancer Res. 2007; 67: 4630-4637.
70. Ishii T, Itoh K, Takahashi S, Sato H, Yanagawa T, Katoh Y, Bannai S and Yamamoto M. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J Biol Chem. 2000; 275: 16023-16029.
71. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD and Yamamoto M. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 1999; 13: 76-86.
72. Zhang DD and Hannink M. Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol Cell Biol. 2003; 23: 8137-8151.
73. Gan L, Johnson DA and Johnson JA. Keap1-Nrf2 activation in the presence and absence of DJ-1. Eur J Neurosci. 2010; 31: 967-977.
74. Fan J, Ren H, Jia N, Fei E, Zhou T, Jiang P, Wu M and Wang G. DJ-1 decreases Bax expression through repressing p53 transcriptional activity. J Biol Chem. 2008; 283: 4022-4030.
75. Kato I, Maita H, Takahashi-Niki K, Saito Y, Noguchi N, Iguchi-Ariga SM and Ariga H. Oxidized DJ-1 inhibits p53 by sequestering p53 from promoters in a DNA-binding affinity-dependent manner. Mol Cell Biol. 2013; 33: 340-359.
76. McNally RS, Davis BK, Clements CM, Accavitti-Loper MA, Mak TW and Ting JP. DJ-1 enhances cell survival through the binding of Cezanne, a negative regulator of NFkappaB. J Biol Chem. 2011; 286: 4098-4106.
77. Liu H, Wang M, Li M, Wang D, Rao Q, Wang Y, Xu Z and Wang J. Expression and role of DJ-1 in leukemia. Biochem Biophys Res Commun. 2008; 375: 477-483.
78. Leslie NR, Bennett D, Lindsay YE, Stewart H, Gray A and Downes CP. Redox regulation of PI 3-kinase signalling via inactivation of PTEN. EMBO J. 2003; 22: 5501-5510.
79. Mo JS, Kim MY, Ann EJ, Hong JA and Park HS. DJ-1 modulates UV-induced oxidative stress signaling through the suppression of MEKK1 and cell death. Cell Death Differ. 2008; 15: 1030-1041.
80. Gu L, Cui T, Fan C, Zhao H, Zhao C, Lu L and Yang H. Involvement of ERK1/2 signaling pathway in DJ-1-induced neuroprotection against oxidative stress. Biochem Biophys Res Commun. 2009; 383: 469-474.
81. Gao H, Yang W, Qi Z, Lu L, Duan C, Zhao C and Yang H. DJ-1 protects dopaminergic neurons against rotenone-induced apoptosis by enhancing ERK-dependent mitophagy. J Mol Biol. 2012; 423: 232-248.
82. Yu HH, Xu Q, Chen HP, Wang S, Huang XS, Huang QR and He M. Stable overexpression of DJ-1 protects H9c2 cells against oxidative stress under a hypoxia condition. Cell Biochem Funct. 2013.
83. Kyriakis JM and Avruch J. Sounding the alarm: protein kinase cascades activated by stress and inflammation. J Biol Chem. 1996; 271: 24313-24316.
84. Verheij M, Bose R, Lin XH, Yao B, Jarvis WD, Grant S, Birrer MJ, Szabo E, Zon LI, Kyriakis JM, Haimovitz-Friedman A, Fuks Z and Kolesnick RN. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature. 1996; 380: 75-79.
85. Gotoh Y and Cooper JA. Reactive oxygen species-and dimerization-induced activation of apoptosis signalregulating kinase 1 in tumor necrosis factor-alpha signal transduction. J Biol Chem. 1998; 273: 17477-17482.
86. Song JJ and Lee YJ. Role of the ASK1-SEK1-JNK1-HIPK1 signal in Daxx trafficking and ASK1 oligomerization. J Biol Chem. 2003; 278: 47245-47252.
87. Junn E, Taniguchi H, Jeong BS, Zhao X, Ichijo H and Mouradian MM. Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death. Proc Natl Acad Sci U S A. 2005; 102: 9691-9696.
88. Karunakaran S, Diwakar L, Saeed U, Agarwal V, Ramakrishnan S, Iyengar S and Ravindranath V. Activation of apoptosis signal regulating kinase 1 (ASK1) and translocation of death-associated protein, Daxx, in substantia nigra pars compacta in a mouse model of Parkinson's disease: protection by alpha-lipoic acid. FASEB J. 2007; 21: 2226-2236.
89. Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, Kawabata M, Miyazono K and Ichijo H. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J. 1998; 17: 2596-2606.
90. Nonn L, Williams RR, Erickson RP and Powis G. The absence of mitochondrial thioredoxin 2 causes massive apoptosis, exencephaly, and early embryonic lethality in homozygous mice. Mol Cell Biol. 2003; 23: 916-922.
91. Conrad M, Jakupoglu C, Moreno SG, Lippl S, Banjac A, Schneider M, Beck H, Hatzopoulos AK, Just U, Sinowatz F, Schmahl W, Chien KR, Wurst W, Bornkamm GW and Brielmeier M. Essential role for mitochondrial thioredoxin reductase in hematopoiesis, heart development, and heart function. Mol Cell Biol. 2004; 24: 9414-9423.
92. Jakupoglu C, Przemeck GK, Schneider M, Moreno SG, Mayr N, Hatzopoulos AK, de Angelis MH, Wurst W, Bornkamm GW, Brielmeier M and Conrad M. Cytoplasmic thioredoxin reductase is essential for embryogenesis but dispensable for cardiac development. Mol Cell Biol. 2005; 25: 1980-1988.
93. Matsui M, Oshima M, Oshima H, Takaku K, Maruyama T, Yodoi J and Taketo MM. Early embryonic lethality caused by targeted disruption of the mouse thioredoxin gene. Dev Biol. 1996; 178: 179-185.
94. Sun QA, Kirnarsky L, Sherman S and Gladyshev VN. Selenoprotein oxidoreductase with specificity for thioredoxin and glutathione systems. Proc Natl Acad Sci U S A. 2001; 98: 3673-3678.
95. Tonissen KF and Di Trapani G. Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy. Mol Nutr Food Res. 2009; 53: 87-103.
96. Kim YC, Masutani H, Yamaguchi Y, Itoh K, Yamamoto M and Yodoi J. Hemin-induced activation of the thioredoxin gene by Nrf2. A differential regulation of the antioxidant responsive element by a switch of its binding factors. J Biol Chem. 2001; 276: 18399-18406.
97. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, Hatayama I, Yamamoto M and Nabeshima Y. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun. 1997; 236: 313-322.
98. Tanito M, Agbaga MP and Anderson RE. Upregulation of thioredoxin system via Nrf2-antioxidant responsive element pathway in adaptive-retinal neuroprotection in vivo and in vitro. Free Radic Biol Med. 2007; 42: 1838-1850.
99. Sakurai A, Nishimoto M, Himeno S, Imura N, Tsujimoto M, Kunimoto M and Hara S. Transcriptional regulation of thioredoxin reductase 1 expression by cadmium in vascular endothelial cells: role of NF-E2-related factor-2. J Cell Physiol. 2005; 203: 529-537.
100. Hirota K, Murata M, Sachi Y, Nakamura H, Takeuchi J, Mori K and Yodoi J. Distinct roles of thioredoxin in the cytoplasm and in the nucleus. A two-step mechanism of redox regulation of transcription factor NF-kappaB. J Biol Chem. 1999; 274: 27891-27897.
101. Lukosz M, Jakob S, Buchner N, Zschauer TC, Altschmied J and Haendeler J. Nuclear redox signaling. Antioxid Redox Signal. 2010; 12: 713-742.
102. Matthews JR, Wakasugi N, Virelizier JL, Yodoi J and Hay RT. Thioredoxin regulates the DNA binding activity of NF-kappa B by reduction of a disulphide bond involving cysteine 62. Nucleic Acids Res. 1992; 20: 3821-3830.
103. Xanthoudakis S and Curran T. Identification and characterization of Ref-1, a nuclear protein that facilitates AP-1 DNA-binding activity. EMBO J. 1992; 11: 653-665.
104. Hirota K, Matsui M, Iwata S, Nishiyama A, Mori K and Yodoi J. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc Natl Acad Sci U S A. 1997; 94: 3633-3638.
105. Ueno M, Masutani H, Arai RJ, Yamauchi A, Hirota K, Sakai T, Inamoto T, Yamaoka Y, Yodoi J and Nikaido T. Thioredoxin-dependent redox regulation of p53-mediated p21 activation. J Biol Chem. 1999; 274: 35809-35815.
106. Ueno M, Matsutani Y, Nakamura H, Masutani H, Yagi M, Yamashiro H, Kato H, Inamoto T, Yamauchi A, Takahashi R, Yamaoka Y and Yodoi J. Possible association of thioredoxin and p53 in breast cancer. Immunol Lett. 2000; 75: 15-20.
107. Jung HJ and Seo YR. Protective effects of thioredoxinmediated p53 activation in response to mild hyperthermia. Oncol Rep. 2012; 27: 650-656.
108. Chen XP, Liu S, Tang WX and Chen ZW. Nuclear thioredoxin-1 is required to suppress cisplatin-mediated apoptosis of MCF-7 cells. Biochem Biophys Res Commun. 2007; 361: 362-366.
109. Lee SR, Yang KS, Kwon J, Lee C, Jeong W and Rhee SG. Reversible inactivation of the tumor suppressor PTEN by H2O2. J Biol Chem. 2002; 277: 20336-20342.
110. Meuillet EJ, Mahadevan D, Berggren M, Coon A and Powis G. Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN's tumor suppressor activity. Arch Biochem Biophys. 2004; 429: 123-133.
111. Sartelet H, Rougemont AL, Fabre M, Castaing M, Duval M, Fetni R, Michiels S, Beaunoyer M and Vassal G. Activation of the phosphatidylinositol 3'-kinase/AKT pathway in neuroblastoma and its regulation by thioredoxin 1. Hum Pathol. 2011; 42: 1727-1739.
112. Zhang R, Al-Lamki R, Bai L, Streb JW, Miano JM, Bradley J and Min W. Thioredoxin-2 inhibits mitochondria-located ASK1-mediated apoptosis in a JNK-independent manner. Circ Res. 2004; 94: 1483-1491.
113. Liu H, Nishitoh H, Ichijo H and Kyriakis JM. Activation of apoptosis signal-regulating kinase 1 (ASK1) by tumor necrosis factor receptor-associated factor 2 requires prior dissociation of the ASK1 inhibitor thioredoxin. Mol Cell Biol. 2000; 20: 2198-2208.
114. Yoo MH, Carlson BA, Gladyshev VN and Hatfield DL. Abrogated Thioredoxin System Causes Increased Sensitivity to TNF-alpha-Induced Apoptosis via Enrichment of p-ERK 1/2 in the Nucleus. PLoS One. 2013; 8: e71427.
115. Nakamura H, Masutani H, Tagaya Y, Yamauchi A, Inamoto T, Nanbu Y, Fujii S, Ozawa K and Yodoi J. Expression and growth-promoting effect of adult T-cell leukemia-derived factor. A human thioredoxin homologue in hepatocellular carcinoma. Cancer. 1992; 69: 2091-2097.
116. Grogan TM, Fenoglio-Prieser C, Zeheb R, Bellamy W, Frutiger Y, Vela E, Stemmerman G, Macdonald J, Richter L, Gallegos A and Powis G. Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival. Hum Pathol. 2000; 31: 475-481.
117. Nakamura H, Bai J, Nishinaka Y, Ueda S, Sasada T, Ohshio G, Imamura M, Takabayashi A, Yamaoka Y and Yodoi J. Expression of thioredoxin and glutaredoxin, redoxregulating proteins, in pancreatic cancer. Cancer Detect Prev. 2000; 24: 53-60.
118. Im JY, Lee KW, Woo JM, Junn E and Mouradian MM. DJ-1 induces thioredoxin 1 expression through the Nrf2 pathway. Hum Mol Genet. 2012; 21: 3013-3024.
119. Malhotra D, Thimmulappa R, Navas-Acien A, Sandford A, Elliott M, Singh A, Chen L, Zhuang X, Hogg J, Pare P, Tuder RM and Biswal S. Decline in NRF2-regulated antioxidants in chronic obstructive pulmonary disease lungs due to loss of its positive regulator, DJ-1. Am J Respir Crit Care Med. 2008; 178: 592-604.
120. Abou-Sleiman PM, Healy DG, Quinn N, Lees AJ and Wood NW. The role of pathogenic DJ-1 mutations in Parkinson's disease. Ann Neurol. 2003; 54: 283-286.
121. Hering R, Strauss KM, Tao X, Bauer A, Woitalla D, Mietz EM, Petrovic S, Bauer P, Schaible W, Muller T, Schols L, Klein C, Berg D, Meyer PT, Schulz JB, Wollnik B, et al. Novel homozygous p. E64D mutation in DJ1 in early onset Parkinson disease (PARK7). Hum Mutat. 2004; 24: 321-329.
122. Aleyasin H, Rousseaux MW, Phillips M, Kim RH, Bland RJ, Callaghan S, Slack RS, During MJ, Mak TW and Park DS. The Parkinson's disease gene DJ-1 is also a key regulator of stroke-induced damage. Proc Natl Acad Sci U S A. 2007; 104: 18748-18753.
123. Jain D, Jain R, Eberhard D, Eglinger J, Bugliani M, Piemonti L, Marchetti P and Lammert E. Age-and dietdependent requirement of DJ-1 for glucose homeostasis in mice with implications for human type 2 diabetes. J Mol Cell Biol. 2012; 4: 221-230.
124. Byun HS, Cho EW, Kim JS, Moon MS, Yum JJ, Kim KC and Kim IG. Thioredoxin overexpression in HT-1080 cells induced cellular senescence and sensitization to gamma radiation. FEBS Lett. 2005; 579: 4055-4062.
125. Komatsu M, Kurokawa H, Waguri S, Taguchi K, Kobayashi A, Ichimura Y, Sou YS, Ueno I, Sakamoto A, Tong KI, Kim M, Nishito Y, Iemura S, Natsume T, Ueno T, Kominami E, et al. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat Cell Biol. 2010; 12: 213-223.
126. Chen W, Sun Z, Wang XJ, Jiang T, Huang Z, Fang D and Zhang DD. Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response. Mol Cell. 2009; 34: 663-673.
127. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997; 275: 1943-1947.
128. Depowski PL, Rosenthal SI and Ross JS. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol. 2001; 14: 672-676.
129. Halvorsen OJ, Haukaas SA and Akslen LA. Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clin Cancer Res. 2003; 9: 1474-1479.
130. Salvesen HB, Stefansson I, Kalvenes MB, Das S and Akslen LA. Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma. Cancer. 2002; 94: 2185-2191.
131. Tachibana M, Shibakita M, Ohno S, Kinugasa S, Yoshimura H, Ueda S, Fujii T, Rahman MA, Dhar DK and Nagasue N. Expression and prognostic significance of PTEN product protein in patients with esophageal squamous cell carcinoma. Cancer. 2002; 94: 1955-1960.
132. Anderson GP and Bozinovski S. Acquired somatic mutations in the molecular pathogenesis of COPD. Trends Pharmacol Sci. 2003; 24: 71-76.
133. Pap T, Franz JK, Hummel KM, Jeisy E, Gay R and Gay S. Activation of synovial fibroblasts in rheumatoid arthritis: lack of Expression of the tumour suppressor PTEN at sites of invasive growth and destruction. Arthritis Res. 2000; 2: 59-64.
134. White ES, Thannickal VJ, Carskadon SL, Dickie EG, Livant DL, Markwart S, Toews GB and Arenberg DA. Integrin alpha4beta1 regulates migration across basement membranes by lung fibroblasts: a role for phosphatase and tensin homologue deleted on chromosome 10. Am J Respir Crit Care Med. 2003; 168: 436-442.
135. Bhatia M, Karlenius TC, Di Trapani G and Tonissen KF. (2013). The interaction between redox and hypoxic signalling pathways in the dynamic oxygen environment of cancer cells. In: Tonissen KF, ed. Carcinogenesis. (Rijeka, Croatia: InTech), pp. 125-152.